A trial comparing chemotherapy for advanced non small cell lung cancer (BTOG1)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Results

Phase:

Phase 3

This trial compared two standard chemotherapy combinations called MVP and MIC with a new combination of docetaxel and carboplatin for advanced non small cell lung cancer.

Doctors usually treat non small cell lung cancer with radiotherapy or surgery. But if the cancer is already advanced when first diagnosed, it can be more difficult to treat. Doctors can then use standard MVP or MIC chemotherapy. MVP is mitomycin, vinblastine and cisplatin and MIC is mitomycin, ifosfamide and cisplatin.

Earlier research showed that docetaxel (Taxotere) and carboplatin may work better than standard treatment.

The aim of the trial was to compare the newer treatment with standard treatment to find out

  • Which treatment works best for advanced non small cell lung cancer
  • More about the side effects and quality of life

Summary of results

The researchers found that docetaxel and carboplatin was no better than standard treatment with MVP or MIC for advanced non small cell lung cancer. But people who had docetaxel and carboplatin reported fewer side effects.

The trial recruited 433 patients aged between 35 and 83 with non small cell lung cancer

  • Half had 4 cycles of treatment with standard MVP or MIC treatment
  • Half had 4 cycles of treatment with docetaxel and carboplatin

The researchers analysed the results in 2006. They looked at the number of people who were alive 2 years after treatment and found there was no difference between the 2 groups. But people in the docetaxel and carboplatin group had a better quality of life after their third cycle of chemotherapy than people in the standard treatment group.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Nick Thatcher

Supported by

Manchester Lung Tumour Group
National Institute for Health Research Cancer Research Network (NCRN)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 140

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think